Boaz Elad, Ledder Oren, Bar-Gil Shitrit Ariella, Dagan Amir, Freund Michael R, Koslowsky Benjamin, Lujan Rona, Greenfeld Shira, Kariv Revital, Loewenberg Weisband Yiska, Lederman Natan, Matz Eran, Dotan Iris, Turner Dan, Yellinek Shlomo
Department of General Surgery, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Crohns Colitis 360. 2025 Mar 31;7(2):otaf025. doi: 10.1093/crocol/otaf025. eCollection 2025 Apr.
In this nationwide study, we aimed to explore healthcare services utilization, medical management, and disease outcomes of inflammatory bowel diseases (IBD) across the 2 major ethnic groups in Israel.
We utilized a cohort including all patients diagnosed with IBD in Israel since 2005. The primary outcome was steroid dependency, with secondary outcomes including use of biologics, time to surgery, and hospitalizations. Outcomes were controlled for possible inherent differences in disease course and phenotype.
Of the 32 491 included patients, 18 252 (56%) had Crohn's disease (CD) and 14 239 (44%) had ulcerative colitis (UC); 10% were Arabs and 90% were Jews. Jewish ethnicity was associated with lower rates of steroid dependency compared to Arab ethnicity in both CD (HR = 0.7 [95% CI, 0.6-0.8]) and UC (HR = 0.7 [95% CI, 0.6-0.8]). The risk of IBD-related surgery in CD was higher in the Arab group at both 3 and 5 years (13% vs. 10%, 16% vs 14%, respectively, = .005). Arabs had more frequent IBD-related hospitalizations than Jews at 5 years (28% vs. 19% with at least 2 hospitalizations, < .001). In contrast, Jewish ethnicity was associated with more frequent use of biologics during the first year from diagnosis in patients with CD (HR = 1.3 [95% CI, 1.1-1.6]) but not with UC.
Arab ethnicity is associated with higher rates of hospitalizations, steroid dependency, and surgeries, and, on the other side, with lower utilization of biologics. Healthcare practitioners and policymakers should address potential cultural and systemic barriers in healthcare delivery in order to improve care across all populations.
在这项全国性研究中,我们旨在探究以色列两大主要族群中炎症性肠病(IBD)的医疗服务利用情况、医疗管理及疾病转归。
我们使用了一个队列,其中包括自2005年以来在以色列被诊断为IBD的所有患者。主要结局为激素依赖,次要结局包括生物制剂的使用、手术时间及住院情况。对疾病病程和表型可能存在的内在差异进行了结局对照。
在纳入的32491例患者中,18252例(56%)患有克罗恩病(CD),14239例(44%)患有溃疡性结肠炎(UC);10%为阿拉伯人,90%为犹太人。在CD(风险比[HR]=0.7[95%置信区间(CI),0.6 - 0.8])和UC(HR=0.7[95%CI,0.6 - 0.8])中,与阿拉伯族裔相比,犹太族裔的激素依赖率较低。在CD中,阿拉伯组在3年和5年时IBD相关手术的风险均较高(分别为13%对10%,16%对14%,P=0.005)。在5年时,阿拉伯人IBD相关住院比犹太人更频繁(至少2次住院的比例为28%对19%,P<0.001)。相比之下,犹太族裔与CD患者诊断后第一年更频繁使用生物制剂相关(HR=1.3[95%CI,1.1 - 1.6]),但与UC无关。
阿拉伯族裔与更高的住院率、激素依赖率及手术率相关,另一方面,与生物制剂的较低利用率相关。医疗从业者和政策制定者应解决医疗服务提供中潜在的文化和系统性障碍,以改善所有人群的医疗护理。